Poltechnet (Sodium Pertechnetate 99mTc Generator)

What Is Poltechnet and What Is It Used For?

Poltechnet belongs to a class of medicines called diagnostic radiopharmaceuticals. Unlike conventional medicines, which are designed to treat a disease, a diagnostic radiopharmaceutical is administered in very small amounts of a radioactive substance so that clinicians can visualize how specific organs or tissues function in real time. The technetium-99m generator is the workhorse of this entire field — technetium-99m is used in roughly 30–40 million diagnostic procedures every year and accounts for approximately 80% of all nuclear medicine imaging worldwide.

A Poltechnet generator consists of a shielded chromatographic column on which molybdenum-99 (99Mo) is adsorbed as molybdate. Molybdenum-99 is a long-lived parent radionuclide (physical half-life 66 hours) that decays to technetium-99m (99mTc, physical half-life 6.02 hours). Because 99Mo is constantly “growing” fresh 99mTc, the generator can be eluted with sterile 0.9% sodium chloride multiple times over its useful life — typically one to two weeks. Each elution yields a sterile, pyrogen-free, pH-neutral solution of sodium pertechnetate (99mTc), ready for patient use or for labeling cold kits.

The resulting sodium pertechnetate (99mTc) solution is classified in the Anatomical Therapeutic Chemical (ATC) system under code V09FX01 — technetium (99mTc) pertechnetate. Regulatory authorities including the European Medicines Agency (EMA) and national licensing bodies such as the UK MHRA, the U.S. FDA and the Swedish Medical Products Agency have authorized it for a wide range of diagnostic indications. The product is supplied exclusively to authorized nuclear medicine centers and is never dispensed to patients directly.

How Does Sodium Pertechnetate (99mTc) Work?

Technetium-99m decays by isomeric transition, emitting a gamma photon with an energy of 140 keV. This photon energy is almost ideal for medical imaging: high enough to escape the patient’s body and be detected externally by a gamma camera, but low enough that it can be efficiently collimated and absorbed by the sodium iodide detector crystals used in single-photon emission computed tomography (SPECT). Because the radionuclide is the only radioactive species used for imaging, the mass of active substance injected is extraordinarily small — usually in the nanogram range — which is why true pharmacological effects are vanishingly rare.

The pertechnetate ion (TcO4−) behaves chemically very much like the iodide ion (I−). It is actively taken up by the sodium/iodide symporter (NIS) in the thyroid gland, the salivary glands, the gastric mucosa and the choroid plexus, but unlike iodide it is not subsequently organified into thyroid hormones. This property allows pertechnetate to function as a rapid, elegant tracer of thyroid uptake and salivary function. It also crosses the blood-brain barrier only where that barrier is disrupted, which makes it useful for detecting certain intracerebral lesions.

When Poltechnet-derived sodium pertechnetate (99mTc) is used to label a “cold kit,” the biodistribution of the finished radiopharmaceutical is determined by the ligand molecule, not by the pertechnetate ion itself. For example, 99mTc-labeled macroaggregated albumin follows pulmonary capillary flow and is used for lung perfusion scans; 99mTc-methylene diphosphonate binds to sites of active bone turnover; and 99mTc-sestamibi concentrates in tissues with high mitochondrial density, such as the myocardium and parathyroid adenomas.

Approved Diagnostic Indications

Sodium pertechnetate (99mTc) eluted from a Poltechnet generator has been approved by regulatory authorities worldwide for the following diagnostic uses, either as a direct tracer or as a radiolabeling precursor:

• Direct injection — thyroid imaging and uptake: Visualization of thyroid morphology, detection of ectopic thyroid tissue (e.g. lingual thyroid), differentiation of hot and cold nodules, evaluation of thyroiditis and follow-up of congenital hypothyroidism.
• Direct injection — salivary gland imaging: Evaluation of salivary gland function in Sjögren’s syndrome, sialadenitis, duct obstruction and following radiotherapy.
• Direct injection — Meckel’s diverticulum scintigraphy: Detection of ectopic gastric mucosa in a suspected Meckel’s diverticulum, a common cause of unexplained gastrointestinal bleeding in children.
• Direct injection — lacrimal gland scintigraphy (dacryoscintigraphy): Evaluation of epiphora and tear duct obstruction.
• Direct injection — micturating cystography: Detection of vesicoureteric reflux, typically in children, as a lower-radiation alternative to X-ray cystography.
• Direct injection — nasolacrimal drainage evaluation and testicular imaging.
• Radiolabeling precursor: Preparation of a wide range of 99mTc-radiopharmaceuticals for bone scintigraphy, myocardial perfusion imaging, renal imaging (DMSA, MAG3, DTPA), pulmonary ventilation/perfusion (V/Q) scans, hepatobiliary imaging, sentinel lymph node localization, infection and inflammation imaging, and tumor imaging.

Because the same eluate can be used for so many different clinical questions, the 99Mo/99mTc generator is considered the cornerstone of modern nuclear medicine service provision. The ability to produce fresh 99mTc on demand in the hospital, rather than relying on long-distance shipment of a short-lived isotope, is the fundamental reason why technetium-99m dominates the specialty.

What Should You Know Before Taking Poltechnet?

Every nuclear medicine examination must be preceded by a careful clinical justification that weighs the anticipated diagnostic benefit against the radiation dose. The referring physician and the nuclear medicine specialist work together to confirm that sodium pertechnetate (99mTc) is the most appropriate tracer for the clinical question, that no recent examination already answers it, and that alternative non-ionizing techniques such as ultrasound or magnetic resonance imaging have been considered where feasible. This stepwise approach is known as the ALARA principle (As Low As Reasonably Achievable) and is codified in European and international radiation protection regulations.

Contraindications

Sodium pertechnetate (99mTc) derived from Poltechnet must not be used in the following situations:

• Hypersensitivity: Known hypersensitivity to sodium pertechnetate, technetium, or to any of the excipients listed in the product information (most formulations contain only sodium chloride, with sodium molybdate on the column).
• Pregnancy (elective examinations): Sodium pertechnetate crosses the placenta and the pertechnetate ion concentrates in the fetal thyroid from the 10th–12th week of gestation, as well as in the fetal bladder. Elective diagnostic procedures must be postponed until after delivery. In urgent cases, the lowest possible activity must be used and the fetal dose estimated.

There is no absolute upper age limit or strict weight-based exclusion, but the suitability of the scan must always be assessed on an individual basis.

Warnings and Precautions

Although sodium pertechnetate (99mTc) has an excellent safety profile, several important precautions apply to every examination. Patients and caregivers should be informed about these in advance so that questions can be answered before the appointment.

Ionizing radiation: Every diagnostic dose of sodium pertechnetate (99mTc) exposes the patient to a small amount of ionizing radiation. The effective dose varies by administered activity and target organ but typically ranges from 0.5 to 10 mSv per examination, comparable to a few months of natural background radiation. Over a lifetime, repeated radiological examinations contribute cumulatively to the stochastic risk of radiation-induced cancer, so each procedure must be individually justified.

Pediatric patients: Children are more radiosensitive than adults because their cells divide faster and they have a longer life expectancy during which a radiation-induced cancer might develop. For this reason, pediatric activities are always scaled down from adult activities according to the EANM Paediatric Dosage Card, which uses a body-mass-based multiplier. The minimum administrable activity recommended by the EANM must still be respected to ensure diagnostic image quality.

Thyroid blocking: Because the pertechnetate ion concentrates in the thyroid gland, in certain 99mTc cold-kit procedures (for example, 99mTc-macroaggregated albumin lung scans, or red blood cell labeling) the thyroid can be pre-blocked with potassium perchlorate or sodium perchlorate. This is at the discretion of the prescribing nuclear medicine physician and is generally not required for direct thyroid scintigraphy itself.

Hydration and bladder emptying: Patients are usually asked to drink plenty of fluids before and after the examination and to void the bladder frequently. This accelerates urinary excretion of free pertechnetate, lowers the radiation dose to the bladder wall and surrounding pelvic organs, and reduces background activity that could interfere with image interpretation.

Renal impairment: Severe renal impairment can prolong the biological half-life of the tracer because urinary excretion is delayed, increasing the radiation dose to the patient. Although this does not usually preclude the examination, the nuclear medicine specialist may adjust the administered activity and imaging protocol.

Recent intake of iodine-containing contrast or thyroid medication: Recent administration of iodine-containing X-ray contrast media, amiodarone or oral/topical iodine antiseptics can block uptake of pertechnetate by the thyroid for several weeks to months. Thyroid hormone replacement therapy and antithyroid drugs also alter thyroid uptake. These factors must be disclosed before the examination to avoid non-diagnostic images.

Radiation protection for staff and close contacts: After injection, patients emit small amounts of gamma radiation until the tracer has decayed and been excreted. Staff follow strict radiation protection procedures. Patients are generally advised to avoid close prolonged contact with pregnant women and infants for the first few hours after the examination, and to follow any specific instructions given by the nuclear medicine department.

Pregnancy and Breastfeeding

Pregnancy status must be confirmed before any examination in women of childbearing potential. A urine or serum beta-hCG test is commonly performed. Detailed advice is provided below.

• Women of childbearing potential: The “10-day rule” or pregnancy test should be applied according to local protocol. If pregnancy cannot be excluded, the examination must be postponed unless clinically urgent.
• Pregnancy: Elective diagnostic use of sodium pertechnetate (99mTc) is contraindicated. If an urgent examination cannot be avoided, the lowest achievable activity should be used, and the absorbed dose to the fetus (including thyroid uptake from the 12th week onward) must be estimated and documented.
• Breastfeeding: Free sodium pertechnetate (99mTc) is excreted into breast milk. The European Association of Nuclear Medicine (EANM) recommends interrupting breastfeeding for a defined period depending on the administered activity. For typical activities used in thyroid scanning, a 12-hour interruption with expression and discarding of milk is usually recommended; for cold-kit labeled products, shorter or no interruption may be adequate. Always follow the specific guidance of the nuclear medicine department.
• Male fertility: Diagnostic doses do not have clinically significant effects on male fertility. No specific contraceptive precautions are required.

Children and Adolescents

Sodium pertechnetate (99mTc) is frequently and safely used in infants, children and adolescents, particularly for thyroid scintigraphy (evaluation of congenital hypothyroidism), Meckel’s diverticulum scans and micturating cystography. Pediatric activities must be scaled according to body weight using the EANM Paediatric Dosage Card. The minimum activity required to obtain diagnostic images should be used, never a simple fixed adult fraction.

Driving and Operating Machinery

Sodium pertechnetate (99mTc) does not produce any known pharmacological effect on alertness, vision or psychomotor performance at the tracer doses used. Patients are usually fit to drive home after the examination, although individual anxiety, sedation used for pediatric patients or underlying medical conditions may affect this. Follow the specific advice of the nuclear medicine department.

How Does Poltechnet Interact with Other Drugs?

Because sodium pertechnetate (99mTc) is injected in nanogram quantities, it does not induce or inhibit cytochrome P450 enzymes and does not compete with other drugs for plasma protein binding in any clinically meaningful way. The concept of a “drug interaction” therefore differs from that for pharmacological medicines: rather than altering blood levels or toxicity, interacting medicines primarily affect how the pertechnetate ion is distributed and excreted, which can in turn influence how the resulting scintigraphic images look.

For this reason it is essential to provide the nuclear medicine department with a complete and up-to-date list of all prescription drugs, over-the-counter products, vitamins and herbal supplements taken in the preceding weeks. In many cases specific medicines must be paused for a defined interval before the examination, and the referring clinician will usually give written instructions.

Major Interactions

The following categories of medicines have the most important effects on sodium pertechnetate (99mTc) biodistribution and frequently require dose timing adjustment, test postponement, or selection of a different tracer.

Minor Interactions

Several additional medicines and dietary factors can subtly affect biodistribution. They rarely require discontinuation, but the interpreting physician should be aware of them.

What Is the Correct Dosage of Poltechnet?

Poltechnet is a generator, not a patient-administered product, and “dosage” in the traditional pharmaceutical sense does not apply to the generator itself. What is administered to patients is the eluate — sodium pertechnetate (99mTc) injection — or a 99mTc-labeled cold-kit radiopharmaceutical prepared from that eluate. The prescribed quantity is expressed in becquerels (Bq), the SI unit of radioactivity, most commonly with the prefix mega (MBq, one million disintegrations per second) or giga (GBq, one billion). Activity is measured in a calibrated dose calibrator immediately before injection because 99mTc decays by 50% every 6.02 hours and the actual activity at injection differs from the calibration time.

Administered activities must always be justified and optimized according to the ALARA principle and to national and international diagnostic reference levels (DRLs). Reference activities vary slightly between the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and national authorities, but they converge on similar ranges for established indications.

Adults — Direct Injection of Sodium Pertechnetate (99mTc)

Children

Pediatric activities are scaled from the adult reference activity using the EANM Paediatric Dosage Card multiplier based on body weight. A minimum administrable activity is defined for each indication to ensure that images remain diagnostic — below that minimum, the signal-to-noise ratio is too poor to answer the clinical question and the child is effectively exposed to radiation for no benefit.

Elderly

No specific dose reduction is required for elderly patients on the basis of age alone. However, elderly patients often have reduced renal function, which can prolong the effective biological half-life of pertechnetate and slightly increase the effective dose to the bladder wall. Good hydration and encouragement of frequent voiding mitigate this effect.

Renal Impairment

Pertechnetate is excreted primarily by the kidneys and to a lesser extent by the gastrointestinal tract. Severe renal impairment does not contraindicate the scan, but the nuclear medicine specialist may slightly reduce the administered activity or adjust imaging timing to account for delayed clearance. Dialysis does not need to be scheduled around the examination for diagnostic activities.

Missed Dose

Because sodium pertechnetate (99mTc) is administered as a single dose on the day of examination in a hospital setting, the concept of a “missed dose” does not apply in the usual sense. If the appointment is missed, it should be rescheduled as soon as practical. The generator elution can be planned around the new appointment.

Overdose

Because the administered activity is calibrated immediately before injection, accidental overdosing is extremely rare. In the unlikely event that a substantially greater activity is administered than intended, the patient’s radiation dose can be reduced by forced diuresis, frequent voiding of the bladder, oral potassium perchlorate to block thyroid uptake, and potentially laxatives or cholestyramine to accelerate fecal excretion. There is no specific pharmacological antidote, and symptomatic management is based on the radiation dose absorbed rather than on the trace chemical mass involved.

What Are the Side Effects of Poltechnet?

Because only nanogram amounts of active substance are injected, sodium pertechnetate (99mTc) does not produce classical pharmacological side effects. The side effects that have been reported are almost exclusively hypersensitivity and injection-site reactions. Large post-marketing surveillance databases and pediatric cohort studies consistently show adverse event rates well below 1 in 10,000 examinations for the eluate itself; reactions to 99mTc cold-kit products are slightly more frequent because the ligand molecules can themselves be immunogenic.

Side Effect Frequency Overview

Radiation-Related Stochastic Effects

Even at the low activities used for diagnostic examinations, ionizing radiation carries a small theoretical long-term risk of stochastic effects — primarily a slightly increased probability of radiation-induced cancer over a lifetime. The risk from a single 99mTc scan is estimated to be in the range of approximately 1 in 10,000 to 1 in 100,000 per examination, depending on age and organ dose, and must be compared with the benefit of obtaining a diagnosis that could materially change clinical management. Deterministic effects such as skin burns or hair loss do not occur at diagnostic doses; these are associated only with interventional fluoroscopy or therapeutic radionuclide administration, not with diagnostic scintigraphy.

Managing Side Effects

If a reaction occurs, it is treated symptomatically. Nuclear medicine departments are equipped with resuscitation equipment and are staffed by personnel trained to recognize and treat rare hypersensitivity reactions, following the same anaphylaxis algorithms used for iodinated contrast media. Mild infusion reactions usually resolve spontaneously within minutes and do not require specific therapy. Extravasation is prevented by careful intravenous technique; if it occurs, elevation and warm compresses generally suffice.

Any side effect, however mild, should be reported to the nuclear medicine staff and recorded in the patient’s medical notes. National pharmacovigilance reporting systems (Yellow Card in the UK, EudraVigilance in the EU, MedWatch in the U.S.) accept reports for radiopharmaceuticals as for any other medicine.

How Should You Store Poltechnet?

Poltechnet is a Class 7 dangerous good (radioactive material) and is therefore subject to a double layer of regulation: pharmaceutical regulation (as a medicine) and radiation protection regulation (as a radioactive source). It is delivered directly from the manufacturer to the nuclear medicine department in a shielded transport container, accompanied by a shipping certificate documenting the activity, reference time and isotopic purity.

Generator Storage

• Original shielding: The generator must remain inside its lead shielded housing at all times, except when the elution cap is accessed. The shielding reduces external dose rates to levels acceptable for staff exposure and for transport.
• Temperature: Store at controlled room temperature, below 25 °C. Do not refrigerate and do not freeze.
• Light: Protect from direct sunlight and strong artificial light.
• Orientation: Keep upright in accordance with the manufacturer’s instructions to preserve column integrity.
• Access: Store in a dedicated, locked radiopharmacy area accessible only to authorized personnel.
• Shelf life: Defined by the molybdenum-99 activity reference; typically up to 2 weeks of useful elution life. Do not use after the expiry date printed on the label.

Eluate Storage

• Immediate use preferred: Sodium pertechnetate (99mTc) eluate is best used as soon as possible after elution to maximize activity and radiochemical purity.
• If retained: Store the eluate vial in its lead pot at room temperature and use within the period specified in the Summary of Product Characteristics, usually up to 8 hours after elution.
• Do not refrigerate or freeze the eluate.

Disposal of the Exhausted Generator

When the generator has been used up, it must be returned to the manufacturer or disposed of as radioactive waste in accordance with national regulations. The residual 99Mo activity continues to decay for several weeks; in many countries, generators are stored in a dedicated decay area until the activity has fallen below clearance limits, after which they may be disposed of as conventional hospital waste if permitted. Patients and visitors should not be allowed unsupervised access to stored or expired generators.

Keep all medicines and radioactive sources out of the sight and reach of children. Never dispose of radioactive materials via ordinary wastewater, household waste or landfill. These rules protect both public health and the environment.

What Does Poltechnet Contain?

Poltechnet is supplied as a sterile generator system. The nuclide of interest, technetium-99m, is not present at the time the generator is manufactured; instead it is continuously produced inside the generator from the decay of molybdenum-99. Understanding the system’s composition helps explain why the finished injection is essentially a dilute saline solution containing only a nanomolar concentration of pertechnetate ion.

Active Substance and Column

• Parent radionuclide: Molybdenum-99 (99Mo), physical half-life 65.94 hours, adsorbed as sodium molybdate (Na2[99MoO4]) onto an aluminium oxide (Al2O3) chromatographic column.
• Daughter radionuclide: Technetium-99m (99mTc), physical half-life 6.02 hours, generated by beta decay of 99Mo and recovered by elution as the pertechnetate anion (99mTcO4−).
• Eluent: Sterile, pyrogen-free 0.9% sodium chloride (saline) supplied either with the generator or separately by the user.
• Final injection: Sodium pertechnetate (99mTc) injection in 0.9% sodium chloride. pH is close to physiological (4.5–7.0 depending on the SmPC). No preservatives are added.

Physical Characteristics

Available Generator Activities

Poltechnet is supplied in a wide range of nominal activities at the reference time (approximately noon on the day of calibration), so that each department can match its expected clinical workload. Typical activities include 2.15, 4.30, 6.45, 8.60, 12.90, 17.20, 21.50, 25.80, 43.00, 60.20, 86.00 and 111.80 GBq. The useful yield of 99mTc per elution is approximately 80% of the 99Mo activity present at that moment, assuming at least 24 hours have elapsed since the last elution (to allow secular equilibrium between parent and daughter to be re-established).

Packaging: Each carton contains one single-use sterile chromatographic column enclosed in a lead shielded housing, an elution needle assembly, and an evacuated eluate vial. Poltechnet is manufactured by the National Centre for Nuclear Research POLATOM (NCBJ POLATOM) in Otwock-Świerk, Poland, one of Europe’s largest radiopharmaceutical producers.